- Record: found
- Abstract: not found
- Article: not found
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials
January 2015
January 2015
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR)
prolong survival in metastatic colorectal cancer (mCRC) Kirsten rat sarcoma viral
oncogene (KRAS) exon 2 wild-type tumors. Recent evidence has suggested that other
RAS mutations (in exons 3 and 4 of KRAS and exons 2, 3 and 4 of a related gene, NRAS)
may also be predictive of resistance.